Surveillance of adamantane resistance among influenza A H3 viruses isolated in Argentina between 2001 and 2007

Revista Argentina de Microbiologia

Volumn 40, Issue 3, 2008, Pages 180-184

  Pontoriero, A ^a   Baumeister, E ^a   Campos, A M ^a   Moreno, A ^a   Cadario, M E ^a   Savy, V ^a  

^a Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

Author keywords

Antivirals; Drug resistance; Hemagglutinin; Influenza; M2 protein

Indexed keywords

AMANTADINE; ASPARAGINE; ASPARTIC ACID; PHENYLALANINE; RIMANTADINE; SERINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; INFLUENZA VIRUS A; NONHUMAN; PHENOTYPE; VIRUS ISOLATION; VIRUS STRAIN;

ADAMANTANE; ARGENTINA; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; TIME FACTORS;

EID: 56649107869     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Barr I, Hurt A, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A (H3) viruses in Australia and neighboring countries in 2005. Antiviral Res 2007; 73: 112-7.
2. Bright R, Medina M, Xu X, Perez-Oronoz G, Wallis T, Davis X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
3. Bright R, Shay D, Shu B, Cox N, Klimov A. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-4.
4. Bush R, Bender C, Subbarao K, Cox N, Fitch W. Predicting the evolution of human influenza A. Science 1999; 286: 1921-5.
5. Felsenstein J. PHYLIP phylogeny inference package, version 3.57. Seattle, Washington, United States. University of Washington, 1993.
6. Govorkova E, Leneva I, Goloubeva O, Bush K, Webster R. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45: 2723-32.
7. Guan Y, Chen H. Resistance to anti-influenza agents. Lancet 2005; 366: 1139-40.
8. Harper S, Fukuda K, Uyeki T, Cox N, Bridges C. Prevention and Control of Influenza. Recommendations of the Advisory Committee of Immunization Practices (ACIP). MMWR 2005; 54: 1-40.
9. Holsinger L, Nichani D, Pinto L, Lamb R. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994; 68: 1551-63.
10. Inoue Y, Yoneda M, Kitahori Y. Dual mutations in the HA1 peptide of amantadine-resistant influenza viruses at positions 193 and 225. Lab Epidemiol Comm 2007; 147-8.
11. Izurieta H, Thompson W, Kramarz P, Shay D, Davis R, De Stefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342: 232-9.
12. Kendal A, Pereira M, Skehel J. Viral isolation. In: Kendal A, Pereira M, Skehel J, editors. Concepts and procedures for laboratory based influenza surveillance. Atlanta, Georgia, United States: Centers for Disease Control and Prevention and Pan American Health Organization; 1982, p. B7-B16.
13. Monto A. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006; 12: 55-60.
14. Puthavathana P, Auewarakul P, Charoenying P, Sangsiriwut K, Pooruk P, Boonnak K, et al. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 2005; 86: 423-33.
15. Saito R, Li D, Shimomura C, Masaki H, Le MQ, Nguyen HL, et al. An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan. Tohoku J Exp Med 2006; 210: 21-7.
16. Simonsen L, Viboud C, Grenfell B, Dushoff J, Jennings L, Smit M, et al. The rapid global spread of reassortant human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 2007; 24: 1811-20.
17. Smith D, Lapedes A, de Jong J, Bestebroer T, Rimmelzwaan G, Osterhaus A, et al.. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 305: 371-6.
18. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 2003; 9: 195-200.
19. Tominack R, Hayden F. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987;1: 459-78.
20. Wang C, Takeuchi K, Pinto L, Lamb R. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67: 5585-94.
21. Ziegler T, Hemphill M, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999;180: 935-9.